On February 8, 2019 Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported an abstract from a prospective phase 2 study conducted in the Netherlands of the use of the Delcath Hepatic CHEMOSAT Delivery System to treat patients with metastatic ocular melanoma with liver metastases, has been accepted for oral presentation and as a poster at the European Conference on Interventional Oncology (ECIO) annual meeting (Press release, Delcath Systems, FEB 8, 2019, View Source;p=RssLanding&cat=news&id=2386758 [SID1234533181]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, Percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath System’s second-generation hemofiltration system: a prospective phase II study, will be presented by T.S. Meijer and M.C. Burgmans, et al of the Leiden University Medical Center in the Netherlands.
The ECIO 2019 conference will take place April 8-11 in Amsterdam, the Netherlands.